Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation.

Leiser, Dominic; Pochon, Benoît; Blank Wieslawa, Elzbieta; Francica, Paola; Glück, Astrid; Aebersold, Daniel; Zimmer, Yitzhak; Medova, Michaela (2014). Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation. FEBS letters, 588(5), pp. 653-658. Elsevier 10.1016/j.febslet.2013.12.025

Text 1-s2.0-S0014579314000192-main.pdf__tid=92ca884c-c7fc-11e4-aae3-00000aab0f26&acdnat=1426085013_2bee987ac525d119a638a6770601912c - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (957kB) | Request a copy

The MET receptor tyrosine kinase is deregulated primarily via overexpression or point mutations in various human cancers and different strategies for MET inhibition are currently evaluated in clinical trials. We observed by Western blot analysis and by Flow cytometry that MET inhibition by different MET small molecule inhibitors surprisingly increases in a dose-dependent manner total MET levels in treated cells. Mechanistically, this inhibition-related MET accumulation was associated with reduced Tyr1003 phosphorylation and MET physical association with the CBL ubiquitin ligase with concomitant decrease in MET ubiquitination. These data may suggest careful consideration for design of anti-MET clinical protocols.

Interest & Impact

Downloads

1 since deposited on 11 Mar 2015
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item